A Phase II Double-Blind, Randomized, Placebo-controlled, Dose Escalation Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary Tuberculosis
Phase of Trial: Phase II
Latest Information Update: 06 Jan 2017
At a glance
- Drugs Tuberculosis vaccine (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors Aeras; Crucell
- 10 Jun 2017 Biomarkers information updated
- 06 Jan 2017 Results assessing safety and immunogenicity published in the American Journal of Respiratory and Critical Care Medicine.
- 18 May 2009 Actual initiation date added from Crucell media release.